Changing payers’ formulary practices is crucial to ensuring that generic versions of complex drugs have a sustainable future in the US, according to Mylan’s chief executive officer, Heather Bresch.
Issuing a “call to action” for senior executives to examine why their health plans were still paying for off-patent originals...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?